Trending Videos
Shorts

0:18
Exploring intranasal PDE5 inhibitor delivery for erectile dysfunction
3 hours ago
by
Melissa Hadley Barrett

0:40
Challenging misconceptions about proximal shunting
a day ago
by
Juan J. Andino, MD, MBA

1:12
Belzutifan plus lenvatinib offers a new option after IO in ccRCC
5 days ago
by
Mina M. Fam, MD

1:01
Decipher score may help guide short-term ADT use
6 days ago
by
Angela Jia, MD, PhD

1:05
Cost-effectiveness model favors beta-3 agonists for OAB
7 days ago
by
Anjali Kapur, MD

1:21
New treatment options complicate BCG-unresponsive NMIBC care
8 days ago
by
Adam B. Weiner, MD(+1 more)

1:29
Why female sexual health is often overlooked in bladder cancer care
9 days ago
by
Armine K. Smith, MD

1:07
How APPs can expand access to clinical trials
14 days ago
by
Mary Dunn, MSN, RN, NP-C, OCN

0:28
What policymakers must do to preserve patient choice
15 days ago
by
Celeste Kirschner, CAE, MHSA

1:14
Why the bladder diary matters in nocturia workup
16 days ago
by
Kari A.O. Tikkinen, MD, PhD
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
2
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
3
Matching mCSPC treatment to the patient, not just the trial data
4
Urocross Expander System enters US commercial use for symptomatic BPH
5































